Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.07.2011 | Brief Report

Breast cancer scalp metastasis as first metastatic site after scalp cooling: Two cases of occurrence after 7- and 9-year follow-up

verfasst von: Julie Lemieux, Christine Desbiens, Jean-Charles Hogue

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy-induced alopecia is a commonly feared chemotherapy side effect and can be prevented using scalp cooling. Scalp metastasis is a rare site of recurrence. There is a question about whether or not the risk might be increased with the use of scalp cooling. Two cases of breast cancer with scalp metastases as first metastatic site are presented. The first patient presented with a scalp metastasis as first metastatic site 9 years following breast cancer chemotherapy treatments; she used scalp cooling for the adjuvant treatment. Second case presented a scalp metastasis as first metastatic site 7 years following treatments for her first cancer; overall, she used scalp cooling in only one of her six adjuvant chemotherapy cycles. Scalp metastases as the first site of recurrence are very rare entities. Scalp cooling is unlikely to have contributed in the cases presented here.
Literatur
3.
Zurück zum Zitat Edelstyn GA, MacDonald M, MacRae KD (1977) Doxorubicin-induced hair loss and possible modification by scalp cooling. Lancet 2(8031):253–254PubMedCrossRef Edelstyn GA, MacDonald M, MacRae KD (1977) Doxorubicin-induced hair loss and possible modification by scalp cooling. Lancet 2(8031):253–254PubMedCrossRef
4.
Zurück zum Zitat Hillen HF, Breed WP, Botman CJ (1990) Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth J Med 37(5–6):231–235PubMed Hillen HF, Breed WP, Botman CJ (1990) Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth J Med 37(5–6):231–235PubMed
5.
Zurück zum Zitat Lemieux J, Amireault C, Provencher L, Maunsell E (2009) Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 118(3):547–552. doi:10.1007/s10549-009-0342-0 PubMedCrossRef Lemieux J, Amireault C, Provencher L, Maunsell E (2009) Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 118(3):547–552. doi:10.​1007/​s10549-009-0342-0 PubMedCrossRef
6.
Zurück zum Zitat Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33(2):297–300PubMedCrossRef Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33(2):297–300PubMedCrossRef
7.
Zurück zum Zitat Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11(6):371–377. doi:10.1007/s00520-003-0451-y PubMed Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11(6):371–377. doi:10.​1007/​s00520-003-0451-y PubMed
8.
Zurück zum Zitat Spaeth D, Luporsi E, Coudert B (2008) Efficacy and safety of cooling helmets for the prevention of chemotherapy-induced alopecia: a prospective study of 911 patients (pts). PASCO 26:517s Spaeth D, Luporsi E, Coudert B (2008) Efficacy and safety of cooling helmets for the prevention of chemotherapy-induced alopecia: a prospective study of 911 patients (pts). PASCO 26:517s
9.
Zurück zum Zitat van den Hurk C, Coebergh J, van de Poll-France L (2008) Some aspects of scalp cooling in breast cancer patients receiving chemotherapy. EJC suppl 6:201 van den Hurk C, Coebergh J, van de Poll-France L (2008) Some aspects of scalp cooling in breast cancer patients receiving chemotherapy. EJC suppl 6:201
11.
Zurück zum Zitat Satterwhite B, Zimm S (1984) The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 54(1):34–37PubMedCrossRef Satterwhite B, Zimm S (1984) The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 54(1):34–37PubMedCrossRef
12.
Zurück zum Zitat Gates O (1937) Cutaneous metastases of malignant disease. Am J Cancer 30:718–730 Gates O (1937) Cutaneous metastases of malignant disease. Am J Cancer 30:718–730
13.
14.
15.
Zurück zum Zitat Fay T (1938) Correlation of body segmental temperature and its relation to the location of carcinomatous metastasis. Surg Gynecol Obstet 66:512–514 Fay T (1938) Correlation of body segmental temperature and its relation to the location of carcinomatous metastasis. Surg Gynecol Obstet 66:512–514
16.
Zurück zum Zitat Lookingbill DP, Spangler N, Helm KF (1993) Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 29(2 Pt 1):228–236PubMedCrossRef Lookingbill DP, Spangler N, Helm KF (1993) Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 29(2 Pt 1):228–236PubMedCrossRef
17.
Zurück zum Zitat Middleton J, Franks D, Buchanan RB, Hall V, Smallwood J, Williams CJ (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69(4):373–375PubMed Middleton J, Franks D, Buchanan RB, Hall V, Smallwood J, Williams CJ (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69(4):373–375PubMed
18.
Zurück zum Zitat Johansen LV (1985) Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol Oncol 24(2):113–116CrossRef Johansen LV (1985) Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol Oncol 24(2):113–116CrossRef
19.
Zurück zum Zitat Witman G, Cadman E, Chen M (1981) Misuse of scalp hypothermia. Cancer Treat Rep 65(5–6):507–508PubMed Witman G, Cadman E, Chen M (1981) Misuse of scalp hypothermia. Cancer Treat Rep 65(5–6):507–508PubMed
20.
Metadaten
Titel
Breast cancer scalp metastasis as first metastatic site after scalp cooling: Two cases of occurrence after 7- and 9-year follow-up
verfasst von
Julie Lemieux
Christine Desbiens
Jean-Charles Hogue
Publikationsdatum
01.07.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1453-y

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.